Litcius/Paper detail

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Tadeusz Kubicki, Paweł Robak, Adam Walter‐Croneck, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd‐Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko‐Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska‐Zubkiewicz, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar Lahoud, Jeffrey A. Zonder, Kent A. Griffith, Andrew Stefka, Ajay Major, Benjamin A. Derman, Andrzej Jakubowiak

2023The Lancet Oncology74 citationsDOIOpen Access PDF

Topics & Concepts

LenalidomideMedicineCarfilzomibMultiple myelomaAutologous stem-cell transplantationDexamethasoneInterim analysisTolerabilityTransplantationPopulationInternal medicineOncologySurgeryClinical trialAdverse effectEnvironmental healthMultiple Myeloma Research and TreatmentsCancer Treatment and PharmacologyChronic Myeloid Leukemia Treatments